Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1889 1
1928 1
1948 2
1950 1
1951 2
1952 1
1954 1
1956 1
1957 2
1958 4
1962 1
1964 1
1965 5
1966 2
1967 2
1968 3
1969 8
1970 8
1971 5
1972 11
1973 5
1974 10
1975 15
1976 9
1977 8
1978 15
1979 12
1980 17
1981 22
1982 10
1983 26
1984 24
1985 21
1986 27
1987 35
1988 52
1989 64
1990 49
1991 77
1992 88
1993 92
1994 85
1995 110
1996 132
1997 156
1998 117
1999 149
2000 141
2001 188
2002 239
2003 271
2004 302
2005 397
2006 464
2007 500
2008 589
2009 704
2010 784
2011 850
2012 866
2013 1035
2014 1197
2015 1394
2016 1501
2017 1542
2018 1852
2019 2097
2020 2231
2021 2251
2022 2338
2023 2339
2024 943

Text availability

Article attribute

Article type

Publication date

Search Results

25,124 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Mota-Freixas
Page 1
BET proteins: Biological functions and therapeutic interventions.
Guo J, Zheng Q, Peng Y. Guo J, et al. Pharmacol Ther. 2023 Mar;243:108354. doi: 10.1016/j.pharmthera.2023.108354. Epub 2023 Feb 3. Pharmacol Ther. 2023. PMID: 36739915 Review.
Abnormal activation of BET proteins is tightly correlated to various human diseases, including cancer. Therefore, BET bromodomain inhibitors (BBIs) were considered as promising therapeutics to treat BET-related diseases, raising >70 clinical trials in the …
Abnormal activation of BET proteins is tightly correlated to various human diseases, including cancer. Therefore, BET bromodom …
Viral Hijacking of BET Proteins.
Chen IP, Ott M. Chen IP, et al. Viruses. 2022 Oct 17;14(10):2274. doi: 10.3390/v14102274. Viruses. 2022. PMID: 36298829 Free PMC article. Review.
Here, we describe how different viruses have evolved to hijack or disrupt host BET protein function through direct interactions with BET family members to support their own propagation. The network of virus-BET interactions emerges as highly intricate, which …
Here, we describe how different viruses have evolved to hijack or disrupt host BET protein function through direct interactions with …
Birch Pollen Allergens.
Li L, Chang C, Guan K. Li L, et al. Curr Protein Pept Sci. 2022;23(11):731-743. doi: 10.2174/1389203723666220815095725. Curr Protein Pept Sci. 2022. PMID: 36523114
Seven birch pollen allergens have been recognized by the International Allergen Nomenclature Sub-committee, with Bet v 1 as the sole major allergen. Component-resolved diagnostics can help to discriminate broad cross-reactivity and false-positive diagnoses of pollen allerg …
Seven birch pollen allergens have been recognized by the International Allergen Nomenclature Sub-committee, with Bet v 1 as the sole …
BET inhibitors: an updated patent review (2018-2021).
Chen H, Liu Z, Zheng L, Wang R, Shi L. Chen H, et al. Expert Opin Ther Pat. 2022 Sep;32(9):953-968. doi: 10.1080/13543776.2022.2115354. Epub 2022 Aug 25. Expert Opin Ther Pat. 2022. PMID: 35982031 Review.
Web of Science, PubMed, SciFinder, WIPO, EPO, USPTO and CNIPA databases were used for searching the literature and patents for BET inhibitors. EXPERT OPINION: In recent years, an increasing number of structurally diverse BET inhibitors have been identified, includin …
Web of Science, PubMed, SciFinder, WIPO, EPO, USPTO and CNIPA databases were used for searching the literature and patents for BET in …
BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications.
To KKW, Xing E, Larue RC, Li PK. To KKW, et al. Molecules. 2023 Mar 29;28(7):3043. doi: 10.3390/molecules28073043. Molecules. 2023. PMID: 37049806 Free PMC article. Review.
Current approaches targeting BET proteins for cancer therapy rely on acetylation mimics to block the bromodomains from binding chromatin. ...In this review, we provided an updated summary about the evolution of small-molecule BET inhibitors. The design of bivalent …
Current approaches targeting BET proteins for cancer therapy rely on acetylation mimics to block the bromodomains from binding chroma …
BET Proteins as Targets for Anticancer Treatment.
Stathis A, Bertoni F. Stathis A, et al. Cancer Discov. 2018 Jan;8(1):24-36. doi: 10.1158/2159-8290.CD-17-0605. Epub 2017 Dec 20. Cancer Discov. 2018. PMID: 29263030 Review.
Bromodomain and extraterminal domain (BET) proteins are epigenetic readers that regulate gene expression and are involved in cancer pathogenesis. ...Adverse events have been observed and may limit treatment compliance. Here, we review the preclinical rationale for targetin …
Bromodomain and extraterminal domain (BET) proteins are epigenetic readers that regulate gene expression and are involved in cancer p …
Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy.
Wang ZQ, Zhang ZC, Wu YY, Pi YN, Lou SH, Liu TB, Lou G, Yang C. Wang ZQ, et al. Signal Transduct Target Ther. 2023 Nov 6;8(1):420. doi: 10.1038/s41392-023-01647-6. Signal Transduct Target Ther. 2023. PMID: 37926722 Free PMC article. Review.
Thus, BET inhibitors represent a novel form of epigenetic anticancer treatment. ...In this paper, we review the function of BET proteins, the preclinical justification for BET protein targeting in cancer, recent advances in small-molecule BET inhibitor …
Thus, BET inhibitors represent a novel form of epigenetic anticancer treatment. ...In this paper, we review the function of BET …
A comprehensive review of BET-targeting PROTACs for cancer therapy.
Zhou XL, Zhao F, Xu YT, Guan YY, Yu T, Zhang YZ, Duan YC, Zhao Y. Zhou XL, et al. Bioorg Med Chem. 2022 Nov 1;73:117033. doi: 10.1016/j.bmc.2022.117033. Epub 2022 Sep 29. Bioorg Med Chem. 2022. PMID: 36202064 Review.
Considering the therapeutic potential of BET proteins in cancer and the marked attractiveness of PROTACs, BET-targeting PROTACs have been extensively pursued. ...In the present review, we provide a comprehensive summary of advances in BET-targeting PROTACs... …
Considering the therapeutic potential of BET proteins in cancer and the marked attractiveness of PROTACs, BET-targeting PROTAC …
BET inhibitors: a novel epigenetic approach.
Doroshow DB, Eder JP, LoRusso PM. Doroshow DB, et al. Ann Oncol. 2017 Aug 1;28(8):1776-1787. doi: 10.1093/annonc/mdx157. Ann Oncol. 2017. PMID: 28838216 Free article. Review.
Currently, several classes of anticancer drugs function at the epigenetic level, including inhibitors of DNA methyltransferase, histone deacetylase (HDAC), lysine-specific demethylase 1, zeste homolog 2, and bromodomain and extra-terminal motif (BET) proteins.BET pr …
Currently, several classes of anticancer drugs function at the epigenetic level, including inhibitors of DNA methyltransferase, histone deac …
Targeting BET bromodomain proteins in solid tumors.
Sahai V, Redig AJ, Collier KA, Eckerdt FD, Munshi HG. Sahai V, et al. Oncotarget. 2016 Aug 16;7(33):53997-54009. doi: 10.18632/oncotarget.9804. Oncotarget. 2016. PMID: 27283767 Free PMC article. Review.
BET inhibitors were initially shown to have efficacy in hematologic malignancies; however, a number of studies have now shown that BET inhibitors can also block progression of non-hematologic malignancies. In this Review, we summarize the efficacy of BET inhi …
BET inhibitors were initially shown to have efficacy in hematologic malignancies; however, a number of studies have now shown that …
25,124 results
You have reached the last available page of results. Please see the User Guide for more information.